This content is only available within our institutional offering.

26 Feb 2025
Hikma Pharmaceuticals (HIK LN, 2290p, Buy) (Results Review) - FY24 results: in line with FY24E, FY25E EBIT also as expected

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Hikma Pharmaceuticals (HIK LN, 2290p, Buy) (Results Review) - FY24 results: in line with FY24E, FY25E EBIT also as expected
Hikma Pharmaceuticals Plc (HIK:LON) | 1,836 275.4 0.8% | Mkt Cap: 4,074m
- Published:
26 Feb 2025 -
Author:
Miles Dixon | Leolie Telford-Cooke -
Pages:
8 -